]>
IRCT20240327061371N1 IRCT 2025-03-02 Esfahan University of Medical Sciences Effect of topical timolol on recurrent epistaxis Effect of topical timolol on recurrent epistaxis: a clinical trial 2024-10-31 anticipated 70 Complete https://irct.ir/trial/79789 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple random: Random allocation rule will be used for random sampling. In this way, 35 cards of the same shape with the name of group A and 35 cards of the same shape with the name of group B are thrown into a container. Then the cards are randomly removed from the container without replacement and the created sequence is recorded, and sampling is also done from Between eligible patients will be based on this sequence, Blinding description: Double-blinding: The placebo will be in the form of normal saline by the pharmacist's colleague in the same containers as the drug spray , which will be poured into the containers and opened after the completion of the coding study. patient and statistician are blinded. In this way, eligible patients referring to otolaryngology outpatient clinics will be assigned to group A or B based on the rule of random assignment. The attending physician is aware of the grouping (A = timolol spray B = placebo spray), the patient will be informed about the procedure based on the explanation of the intervention method and obtaining informed consent, but he does not know the allocation to the study group. The groups will not be notified and it only knows A and B groups. 3 epistaxis. Intervention 1: Intervention group: half percent timolol nasal spray manufactured by Raha Pharmaceutical Company, one puff in each nostril twice a day for 4 weeks. Intervention 2: Control group: Normal saline nasal spray made by Faculty of Pharmacy, one puff in each nostril twice a day for 4 weeks. No - There is not a plan to make this available Justification or reason for not sharing IPD is No more information
public Afrooz Eshaghian
Kashani Hospital, Kashani St.
Isfahan Iran (Islamic Republic of) ۸۱۸۳۹۸۳۴۳۴ +98 31 3233 0091 afroozeshaghian@med.mui.ac.ir Esfahan University of Medical Sciences scientific Afrooz Eshaghian
Kashani Hospital, Kashani St.
Isfahan Iran (Islamic Republic of) ۸۱۸۳۹۸۳۴۳۴ +98 31 3233 0091 afroozeshaghian@gmail.com Esfahan University of Medical Sciences Iran (Islamic Republic of) History of recurrent epistaxis with at least 4 episodes in the last four weeks no limit no limit Both Pregnancy Having bronchial asthma or chronic lung disease Suffering from diseases that cause coagulation problems, such as hemophilia Patients with low blood pressure Having pheochromocytoma or severe peripheral blood circulation disorders Receiving calcium antagonists History of nose surgery in the last month breastfeeding Having chronic lung disease Patients with heart failure Patients with bradycardia Patients with other cardiac contraindications for beta-blockers Patients with peripheral vascular circulation dysfunction Receiving amiodarone Receiving antiarrhythmics Receiving clonidine Receiving lidocaine Receiving beta blockers Receiving fluctafenine Receiving soltopride Hypersensitivity to timolol Use of anticoagulants R04.0 Epistaxis Treatment - Drugs Treatment - Drugs Intervention group: half percent timolol nasal spray manufactured by Raha Pharmaceutical Company, one puff in each nostril twice a day for 4 weeks. Control group: Normal saline nasal spray made by Faculty of Pharmacy, one puff in each nostril twice a day for 4 weeks. Epistaxis. Timepoint: Before the intervention and 2 weeks, 4 weeks, and 8 weeks after the intervention. Method of measurement: History taking. Esfahan University of Medical Sciences Approved 2024-10-12 Ethics Committee of Faculty of Medicine - Isfahan University of Medical Sciences Faculty of Medicine, Isfahan University of Medical Sciences, hezar jarib St Isfahan Isfehan Iran (Islamic Republic of)